CORTICOSTEROID REDUCTION OR DISCONTINUATION AFTER INITIATION OF AVATROMBOPAG TREATMENT IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
Author(s): ,
Michael Recht
Affiliations:
Oregon Health & Science University,Portland,United States;American Thrombosis and Hemostasis Network,Rochester,United States
,
Amy Dixon
Affiliations:
Dova Pharmaceuticals,Durham,United States
,
Kavita Aggarwal
Affiliations:
Dova Pharmaceuticals,Durham,United States
Michael Vredenburg
Affiliations:
Dova Pharmaceuticals,Durham,United States
(Abstract release date: 05/14/20) EHA Library. Vredenburg M. 06/12/20; 294138; EP1657
Michael Vredenburg
Michael Vredenburg
Contributions
Abstract

Abstract: EP1657

Type: e-Poster

Background
ITP is an immune-mediated disease resulting in platelet destruction and diminished platelet production.  Corticosteroids are often used as first line treatment for ITP.  New societal guidelines and an international consensus statement (Neunert, 2019 and Provan, 2019) suggest limiting the utilization of corticosteroids in ITP patients due to untoward side effects and safety concerns.  Ideally, second line treatment options in ITP would allow for dose reduction or discontinuation of steroids.  Avatrombopag (AVA) is an oral thrombopoietin-receptor agonist approved for adult patients with chronic ITP who have failed a previous treatment. 

Aims
The objective of these analyses was to characterize the reduction in baseline corticosteroid use in patients who received AVA for the treatment of chronic ITP.

Methods
A 6-month, multicenter, randomized, double-blind, phase 3 study enrolled 32 AVA and 17 placebo-treated patients with chronic ITP.  Eligible patients could enter a 96-week open-label extension period following the core study. Stable doses of corticosteroids were allowed at baseline and continued use was permitted. During weeks 6 to 18 of the core study and after the first 6 weeks of the extension, the investigator was allowed to decrease the dose and/or discontinue the use of corticosteroids in conjunction with study drug titration if needed. The proportion of patients able to reduce corticosteroid use without the need for rescue treatment during either the core or extension phase of the study was evaluated.    

Results
At baseline, 14 AVA and 7 placebo-treated patients used baseline concomitant corticosteroid medication. Six patients originally randomized to AVA (42.9%) were able to either reduce or discontinue baseline concomitant corticosteroid. During the extension, patients who received placebo during the core study were switched to AVA, and 4 additional patients were subsequently able to reduce corticosteroid dose (57.1%).

Conclusion
Avatrombopag use allowed for the reduction or discontinuation of corticosteroids in ITP patients.

Session topic: 32. Platelets disorders

Keyword(s): Bleeding disorder, Immune thrombocytopenia (ITP), Thrombopoietin (TPO)

Abstract: EP1657

Type: e-Poster

Background
ITP is an immune-mediated disease resulting in platelet destruction and diminished platelet production.  Corticosteroids are often used as first line treatment for ITP.  New societal guidelines and an international consensus statement (Neunert, 2019 and Provan, 2019) suggest limiting the utilization of corticosteroids in ITP patients due to untoward side effects and safety concerns.  Ideally, second line treatment options in ITP would allow for dose reduction or discontinuation of steroids.  Avatrombopag (AVA) is an oral thrombopoietin-receptor agonist approved for adult patients with chronic ITP who have failed a previous treatment. 

Aims
The objective of these analyses was to characterize the reduction in baseline corticosteroid use in patients who received AVA for the treatment of chronic ITP.

Methods
A 6-month, multicenter, randomized, double-blind, phase 3 study enrolled 32 AVA and 17 placebo-treated patients with chronic ITP.  Eligible patients could enter a 96-week open-label extension period following the core study. Stable doses of corticosteroids were allowed at baseline and continued use was permitted. During weeks 6 to 18 of the core study and after the first 6 weeks of the extension, the investigator was allowed to decrease the dose and/or discontinue the use of corticosteroids in conjunction with study drug titration if needed. The proportion of patients able to reduce corticosteroid use without the need for rescue treatment during either the core or extension phase of the study was evaluated.    

Results
At baseline, 14 AVA and 7 placebo-treated patients used baseline concomitant corticosteroid medication. Six patients originally randomized to AVA (42.9%) were able to either reduce or discontinue baseline concomitant corticosteroid. During the extension, patients who received placebo during the core study were switched to AVA, and 4 additional patients were subsequently able to reduce corticosteroid dose (57.1%).

Conclusion
Avatrombopag use allowed for the reduction or discontinuation of corticosteroids in ITP patients.

Session topic: 32. Platelets disorders

Keyword(s): Bleeding disorder, Immune thrombocytopenia (ITP), Thrombopoietin (TPO)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies